Provectus Biopharmaceuticals Announces Presentation of Preliminary Data from Combination Therapy Trial of PV-10® and KEYTRUDA® for Checkpoint-Refractory Advanced Cutaneous Melanoma at ESMO Virtual Congress 2020
September 17, 2020 07:00 ET
|
Provectus Biopharmaceuticals Inc.
36% ORR and 64% DCR (RECIST 1.1)PV-10-induced, tumor-specific restoration of T cell functionData compare favorably to approved and investigational therapies for patient population KNOXVILLE, TN,...
Provectus Names Frank Akers, PhD to Company’s Strategic Advisory Board
July 29, 2019 08:00 ET
|
Provectus Biopharmaceuticals Inc.
Dr. Akers to assist Provectus develop and manage new Company scientific advisory board KNOXVILLE, TN, July 29, 2019 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced the addition of...
Provectus Appoints Heather Raines, CPA as Chief Financial Officer
March 25, 2019 08:00 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, March 25, 2019 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced the appointment of Heather Raines as the Company’s Chief Financial Officer (CFO). Mrs. Raines had previously...
PROVECTUS ANNOUNCES GRANT OF ORPHAN DRUG DESIGNATION IN U.S. TO PV-10 FOR TREATMENT OF OCULAR MELANOMA
February 12, 2019 07:30 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Feb. 12, 2019 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that orphan drug designation (ODD) status was granted by the U.S. Food and Drug Administration (FDA) to small...
PROVECTUS BIOPHARMACEUTICALS AND PEDIATRIC ONCOLOGY EXPERIMENTAL THERAPEUTICS INVESTIGATORS' CONSORTIUM (POETIC) ANNOUNCE PV-10 ABSTRACT AT AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING
May 17, 2018 08:00 ET
|
Provectus Biopharmaceuticals Inc.
FOR IMMEDIATE RELEASE Research undertaken at POETIC member institutions Alberta Children’s Hospital (Canada) and Memorial Sloan Kettering Cancer Center identifies PV-10 activity, mechanisms of...
STUDY OF T CELL MEDIATED IMMUNITY FROM COMBINATION OF PV-10 AND IMMUNE CHECKPOINT BLOCKADE IN MURINE MELANOMA MODELS PUBLISHED IN PLOS ONE
April 30, 2018 09:00 ET
|
Provectus Biopharmaceuticals Inc.
FOR IMMEDIATE RELEASE Combinations with PV-10 included + anti-CTLA-4; + anti-PD-1; + anti-PD-L1; and, + anti-PD-1 + Treg depletion Data provided basis for ongoing Phase 1b/2 study of PV-10 in...
PROVECTUS BIOPHARMACEUTICALS AND PEDIATRIC ONCOLOGY EXPERIMENTAL THERAPEUTICS INVESTIGATORS' CONSORTIUM (POETIC) ANNOUNCE ACCEPTANCE OF PV-10 POSTER PRESENTATION AT AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING
April 25, 2018 16:00 ET
|
Provectus Biopharmaceuticals Inc.
FOR IMMEDIATE RELEASE Preclinical pediatric cancer research undertaken at POETIC member institutions Alberta Children’s Hospital (Canada) and Memorial Sloan Kettering Cancer Center KNOXVILLE,...
PROVECTUS Announces Resolution of SEC Investigation
December 12, 2017 16:19 ET
|
Provectus Biopharmaceuticals Inc.
– SEC “takes into account the proactive remediation and cooperation by the [C]ompany’s new leadership” – – No monetary penalties; Commission notes actions already taken by Provectus to remedy...
PROVECTUS ANNOUNCES RESULTS FROM MECHANISM OF ACTION STUDY OF TOPICAL PH-10 FOR THE TREATMENT OF PSORIASIS
November 30, 2017 06:00 ET
|
Provectus Biopharmaceuticals Inc.
– Responses mediated by multiple pathways, including IL-17, IL-22 and interferons – – Down-regulation of more than 500 disease-related genes; wide range of central “psoriasis-related” genes...
PROVECTUS BIOPHARMACEUTICALS RECEIVES SECOND CANCER COMBINATION THERAPY PATENT FROM THE UNITED STATES PATENT AND TRADEMARK OFFICE
November 07, 2017 16:00 ET
|
Provectus Biopharmaceuticals Inc.
– Protection expands coverage for combinations of intralesional PV-10 with anti-PD-1 and anti-PD-L1 agents for melanoma and cancers of the liver – KNOXVILLE, TN, Nov. 07, 2017 (GLOBE NEWSWIRE)...